Bristol Myers Squibb says it expects to cancel some drug development programmes due to US government drug pricing rules that are due to be phased in from next year...
The proposed expansion to the Inflation Reduction Act would substantially harm U.S. biopharma, triggering hundreds of thousands of job...
Pharmaceutical companies are delaying, or outright canceling, the development of new medicines following new drug rules signed into law...
The passage of last year’s Inflation Reduction Act (IRA) made major structural changes to the way Medicare covers and pays for...